CONNAUGHT TYPHIM Vi IS FIRST SINGLE-DOSE TYPHOID VACCINE available in the U.S. following its approval for marketing by the IDA on Nov. 28. The injectable typhoid Vi polysaccharide vaccine was approved for prevention of typhoid fever caused by Salmonella typhi in persons two years of age and older. The single intramuscular dose of 5 ml "increases the likelihood of patient compliance" over oral or injectable multi-dose, alternate-day regimens. The injectable multi-dose formulation is "highly reactogenic," Swiftwater, Penn.-based Connaught commented.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Darko has become the first director-general of the AMA, an organization set up to transform access to quality-assured medicines across Africa and foster a more predictable, efficient regulatory environment for innovation.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
